Magnetic resonance–guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson's disease and essential tremor cases

Restricted access

OBJECTIVE

Thalamotomy of the ventral intermediate nucleus (VIM) is effective in alleviating medication-resistant tremor in patients with essential tremor (ET) and Parkinson's disease (PD). MR-guided focused ultrasound (MRgFUS) is an innovative technology that enables noninvasive thalamotomy via thermal ablation.

METHODS

Patients with severe medication-resistant tremor underwent unilateral VIM thalamotomy using MRgFUS. Effects on tremor were evaluated using the Clinical Rating Scale for Tremor (CRST) in patients with ET and by the motor part of the Unified Parkinson's Disease Rating Scale (UPDRS) in patients with PD and ET-PD (defined as patients with ET who developed PD many years later). Quality of life in ET was measured by the Quality of Life in Essential Tremor (QUEST) questionnaire and in PD by the PD Questionnaire (PDQ-39).

RESULTS

Thirty patients underwent MRgFUS, including 18 with ET, 9 with PD, and 3 with ET-PD. The mean age of the study population was 68.9 ± 8.3 years (range 46–87 years) with a mean disease duration of 12.1 ± 8.9 years (range 2–30 years). MRgFUS created a lesion at the planned target in all patients, resulting in cessation of tremor in the treated hand immediately following treatment. At 1 month posttreatment, the mean CRST score of the patients with ET decreased from 40.7 ± 11.6 to 9.3 ± 7.1 (p < 0.001) and was 8.2 ± 5.0 six months after treatment (p < 0.001, compared with baseline). Average QUEST scores decreased from 44.8 ± 12.9 to 13.1 ± 13.2 (p < 0.001) and was 12.3 ± 7.2 six months after treatment (p < 0.001). In patients with PD, the mean score of the motor part of the UPDRS decreased from 24.9 ± 8.0 to 16.4 ± 11.1 (p = 0.042) at 1 month and was 13.4 ± 9.2 six months after treatment (p = 0.009, compared with baseline). The mean PDQ-39 score decreased from 38.6 ± 16.8 to 26.1 ± 7.2 (p = 0.036) and was 20.6 ± 8.8 six months after treatment (p = 0.008). During follow-up of 6–24 months (mean 11.5 ± 7.2 months, median 12.0 months), tremor reappeared in 6 of the patients (2 with ET, 2 with PD, and 2 with ET-PD), to a lesser degree than before the procedure in 5. Adverse events that transiently occurred during sonication included headache (n = 11), short-lasting vertigo (n = 14) and dizziness (n = 4), nausea (n = 3), burning scalp sensation (n = 3), vomiting (n = 2) and lip paresthesia (n = 2). Adverse events that lasted after the procedure included gait ataxia (n = 5), unsteady feeling (n = 4), taste disturbances (n = 4), asthenia (n = 4), and hand ataxia (n = 3). No adverse event lasted beyond 3 months. Patients underwent on average 21.0 ± 6.9 sonications (range 14–45 sonications) with an average maximal sonication time of 16.0 ± 3.0 seconds (range 13–24 seconds). The mean maximal energy reached was 12,500 ± 4274 J (range 5850–23,040 J) with a mean maximal temperature of 56.5° ± 2.2°C (range 55°–60°C).

CONCLUSIONS

MRgFUS VIM thalamotomy to relieve medication-resistant tremor was safe and effective in patients with ET, PD, and ET-PD. Current results emphasize the superior adverse events profile of MRgFUS over other surgical approaches for treating tremor with similar efficacy. Large randomized studies are needed to assess prolonged efficacy and safety.

ABBREVIATIONS AC-PC = anterior commissure-posterior commissure; CRST = Clinical Rating Scale for Tremor; DBS = deep brain stimulation; ET = essential tremor; MRgFUS = MR-guided focused ultrasound; PD = Parkinson's disease; PDQ-39 = PD Questionnaire; QUEST = Quality of Life in Essential Tremor; RF = radiofrequency; UPDRS = Unified Parkinson's Disease Rating Scale; VIM = ventral intermediate nucleus.

Article Information

Correspondence Menashe Zaaroor, Department of Neurosurgery, Rambam Health Care Campus, PO Box 9602, Haifa 31096, Israel. email: m_zaaroor@rambam.health.gov.il.

INCLUDE WHEN CITING Published online February 24, 2017; DOI: 10.3171/2016.10.JNS16758.

Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    Axial T2-weighted MR images. The slice of the target is presented at 3 time points: 1 day after the procedure (A), 1 week after the procedure (B), and 2 months after the procedure (C). Lesion size and surrounding edema slightly increased on the 1-week postprocedural scan. On the 2-month postprocedural scan, all lesions had decreased in size and the edema surrounding the lesion in the first week had resolved.

References

1

Bauer RMartin EHaegele-Link SKaegi Gvon Specht MWerner B: Noninvasive functional neurosurgery using transcranial MR imaging-guided focused ultrasound. Parkinsonism Relat Disord 20:Suppl 1S197S1992014

2

Benabid ALPollak PLouveau AHenry Sde Rougemont J: Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 50:3443461987

3

Campbell AMGlover JChiang VLSGerrard JYu JB: Gamma Knife stereotactic radiosurgical thalamotomy for intractable tremor: a systematic review of the literature. Radiother Oncol 114:2963012015

4

Chang WSJung HHKweon EJZadicario ERachmilevitch IChang JW: Unilateral magnetic resonance guided focused ultrasound thalamotomy for essential tremor: practices and clinicoradiological outcomes. J Neurol Neurosurg Psychiatry 86:2572642015

5

Chang WSJung HHZadicario ERachmilevitch ITlusty TVitek S: Factors associated with successful magnetic resonance-guided focused ultrasound treatment: efficiency of acoustic energy delivery through the skull. J Neurosurg 124:4114162016

6

Elias WJHuss DVoss TLoomba JKhaled MZadicario E: A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med 369:6406482013

7

Fahn SElton R: Unified Parkinson's Disease Rating Scale, in Fahn S, Marsden CD, Calne DB, et al (eds): Recent Developments in Parkinson's Disease.. Florham Park, NJMacmillan Health Care Information1987. 3163

8

Fasano ADeuschl G: Therapeutic advances in tremor. Mov Disord 30:155715652015

9

Fishman PS: Paradoxical aspects of parkinsonian tremor. Mov Disord 23:1681732008

10

Frighetto LBizzi JAnnes RDSilva Rdos SOppitz P: Stereotactic radiosurgery for movement disorders. Surg Neurol Int 3:Suppl 1S10S162012

11

Gallay MNMoser DRossi FPourtehrani PMagara AEKowalski M: Incisionless transcranial MR-guided focused ultrasound in essential tremor: cerebellothalamic tractotomy. J Ther Ultrasound 4:52016

12

Hooper AKOkun MSFoote KDFernandez HHJacobson CZeilman P: Clinical cases where lesion therapy was chosen over deep brain stimulation. Stereotact Funct Neurosurg 86:1471522008

13

Hughes AJDaniel SEKilford LLees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:1811841992

14

Jeanmonod DWerner BMorel AMichels LZadicario ESchiff G: Transcranial magnetic resonance imaging-guided focused ultrasound: noninvasive central lateral thalamotomy for chronic neuropathic pain. Neurosurg Focus 32:1E12012

15

Lim SYHodaie MFallis MPoon YYMazzella FMoro E: Gamma Knife thalamotomy for disabling tremor: a blinded evaluation. Arch Neurol 67:5845882010

16

Limousin PSpeelman JDGielen FJanssens M: Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. J Neurol Neurosurg Psychiatry 66:2892961999

17

Lipsman NSchwartz MLHuang YLee LSankar TChapman M: MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study. Lancet Neurol 12:4624682013

18

Litvan IBhatia KPBurn DJGoetz CGLang AEMcKeith I: Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 18:4674862003

19

Martin EJeanmonod DMorel AZadicario EWerner B: High-intensity focused ultrasound for noninvasive functional neurosurgery. Ann Neurol 66:8588612009

20

Nagaseki YShibazaki THirai TKawashima YHirato MWada H: Long-term follow-up results of selective VIM-thalamotomy. J Neurosurg 65:2963021986

21

Okun MSStover NPSubramanian TGearing MWainer BHHolder CA: Complications of Gamma Knife surgery for Parkinson disease. Arch Neurol 58:199520022001

22

Rodriguez-Oroz MCMoro EKrack P: Long-term outcomes of surgical therapies for Parkinson's disease. Mov Disord 27:171817282012

23

Schlesinger IEran ASinai AErikh INassar MGoldsher D: MRI guided focused ultrasound thalamotomy for moderate-to-severe tremor in Parkinson's disease. Parkinsons Dis 2015:2191492015

24

Schrag AKeens JWarner J: Ropinirole for the treatment of tremor in early Parkinson's disease. Eur J Neurol 9:2532572002

25

Schuepbach WMMRau JKnudsen KVolkmann JKrack PTimmermann L: Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 368:6106222013

26

Schuurman PRBosch DABossuyt PMMBonsel GJvan Someren EJWde Bie RMA: A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med 342:4614682000

27

Tasker RRSiqueira JHawrylyshyn POrgan LW: What happened to VIM thalamotomy for Parkinson's disease?. Appl Neurophysiol 46:68831983

28

Thenganatt MAJankovic J: The relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord 22:Suppl 1S162S1652016

29

Walter BLVitek JL: Surgical treatment for Parkinson's disease. Lancet Neurol 3:7197282004

30

Weintraub DElias WJ: The emerging role of transcranial magnetic resonance imaging-guided focused ultrasound in functional neurosurgery. Mov Disord [epub ahead of print] 2016

31

Young RFLi FVermeulen SMeier R: Gamma Knife thalamotomy for treatment of essential tremor: long-term results. J Neurosurg 112:131113172010

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 137 137 57
Full Text Views 370 370 49
PDF Downloads 183 183 25
EPUB Downloads 0 0 0

PubMed

Google Scholar